Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Less: amount representing interest Operating And Finance Lease Liability, Undiscounted Excess Amount Operating And Finance Lease Liability, Undiscounted Excess Amount Statistical Measurement Statistical Measurement [Domain] Non-cash royalty revenue related to sale of future royalties Non-Cash Royalty Revenue Related To Sale Of Future Royalties Non-Cash Royalty Revenue Related To Sale Of Future Royalties Award Timing Predetermined Award Timing Predetermined [Flag] 2026 (remaining) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Entity File Number Entity File Number Additional paid-in capital Additional Paid-in Capital [Member] Other Noncurrent Assets Other Noncurrent Assets [Member] Payments of deferred offering costs Payments of Financing Costs Going Concern Liquidity [Policy Text Block] Liquidity Tabular List, Table Tabular List [Table Text Block] Leases [Abstract] Leases [Abstract] Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Other indirect costs Other Indirect Costs [Member] Other Indirect Costs Royalty payments Payments for Royalties License License [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Measurement Basis [Axis] Measurement Basis [Axis] Class of warrant or right, outstanding Class of Warrant or Right, Outstanding Loss per common share - basic (in usd per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Cumulative total received from grants Cumulative Total Received From Grants Cumulative Total Received From Grants Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Amended and Restated 2014 Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan Milestone payments, contingent amount Milestone Payments, Contingent Amount Milestone payments, contingent amount. Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Pear Tree Pharmaceuticals, Inc. Pear Tree Pharmaceuticals, Inc. [Member] Pear Tree Pharmaceuticals, Inc. Adjustment to Compensation, Amount Adjustment to Compensation Amount December 2023 Warrants December 2023 Warrants [Member] December 2023 Warrants Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Employee Stock Option Share-Based Payment Arrangement, Option [Member] March 2023 At The Market Sales Agreement March 2023 At The Market Sales Agreement [Member] March 2023 At The Market Sales Agreement Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Preferred stock, convertible, public offering, share price trigger Preferred Stock, Convertible, Public Offering, Share Price Trigger Preferred Stock, Convertible, Public Offering, Share Price Trigger Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts and Financing Receivables [Table] Antidilutive Securities Antidilutive Securities [Axis] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Insider Trading Policies and Procedures [Line Items] Stock-based compensation expense Share-Based Payment Arrangement, Expense Common stock, shares authorized (in shares) Common Stock, Shares Authorized Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Current assets Assets, Current [Abstract] Canceled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders' equity Liabilities and Equity Contra R&D expenses Contra Research And Development Expense, Indirect Costs Contra Research And Development Expense, Indirect Costs Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Grant, DARE-PTB1 Grant, DARE-PTB1 [Member] Grant, DARE-PTB1 Licensing Agreements Licensing Agreements [Member] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Cover [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Maximum Maximum [Member] Selling, general and administrative General and Administrative Expense [Member] Exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Convertible preferred stock, shares reserved for future issuance Convertible Preferred Stock, Shares Reserved for Future Issuance Accounting Policies [Abstract] Accounting Policies [Abstract] Schedule of Operating Lease Liabilities Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Class of Warrant or Right Class of Warrant or Right [Axis] Present value of lease liabilities Operating Lease, Liability Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Amortization of finance lease Finance Lease, Right-of-Use Asset, Amortization Entity Shell Company Entity Shell Company Underlying Awards Granted Under the Amended 2014 Plan Underlying Awards Granted Under the Amended Two Thousand Fourteen Plan [Member] Underlying Awards Granted Under the Amended Two Thousand Fourteen Plan Amount awarded for grant Proceeds From Award Of Grants Proceeds From Award Of Grants Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and development funding percentage Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred, For General And Administrative Expenses, Percentage Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred, For General And Administrative Expenses, Percentage Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Name Measure Name Other receivables Other Receivables Schedule of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Finance lease, incremental borrowing rate, prime rate Finance Lease, Incremental Borrowing Rate, Prime Rate Finance Lease, Incremental Borrowing Rate, Prime Rate Current portion of lease liabilities, operating Operating Lease, Liability, Current Common stock issuable upon exercise or conversion of the securities underlying the Agent Units Selling Agent Unit Warrants [Member] Selling Agent Unit Warrants License and services agreement term License And Services Agreement, Term License And Services Agreement, Term Class of Stock [Line Items] Class of Stock [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Award Timing Method Award Timing Method [Text Block] Preferred stock, convertible, share price trigger Preferred Stock, Convertible, Share Price Trigger Preferred Stock, Convertible, Share Price Trigger Award Type Award Type [Axis] Legal Entity Legal Entity [Axis] Total assets Assets Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Research And Development Services Research And Development Services [Member] Research And Development Services Cash flows from investing activities Cash Provided by (Used in) Investing Activity, Continuing Operation [Abstract] Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Trading Symbol Trading Symbol Preeclampsia Agreement Preeclampsia Agreement [Member] Preeclampsia Agreement Cash, Cash Equivalents, and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell [Member] National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell Entity Address, City or Town Entity Address, City or Town Weighted-average discount rate, Finance leases Finance Lease, Weighted Average Discount Rate, Percent Additional investment amount Class Of Warrant Or Right, Supplement Investment Class Of Warrant Or Right, Supplement Investment Beneficial ownership percentage Beneficial Ownership Percentage Beneficial Ownership Percentage Effect of exchange rate changes on cash and cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Total research and development direct program costs Research And Development Expense, Direct Program Costs, Net Research And Development Expense, Direct Program Costs, Net Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Income Statement Location Statement of Income Location, Balance [Domain] Finance lease payment due included in accounts payable Finance Lease Payment Due Included In Accounts Payable Finance Lease Payment Due Included In Accounts Payable Foundation Foundation [Member] Foundation Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Class of warrant or right, extent holder own percentage (more than) Class of Warrant or Right, Extent Holder Own Percentage Class of Warrant or Right, Extent Holder Own Percentage Entity Emerging Growth Company Entity Emerging Growth Company Commission percent Percentage Of Aggregate Commission Percentage of aggregate commission. 2027 Finance Lease, Liability, to be Paid, Year One Common stock warrants Warrant [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Weighted-average remaining lease term, Finance leases (in years) Finance Lease, Weighted Average Remaining Lease Term Remeasurement of operating lease right-of-use assets and lease liabilities due to lease modification Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Debt issuance cost Debt Issuance Costs, Net Level 2 Fair Value, Inputs, Level 2 [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Business Combination Business Combination [Domain] Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Less: amount representing interest Finance Lease, Liability, Undiscounted Excess Amount Related Party Related Party [Member] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Preferred stock, convertible, threshold consecutive trading days Preferred Stock, Convertible, Threshold Consecutive Trading Days Preferred Stock, Convertible, Threshold Consecutive Trading Days Conversion of stock, issued (in shares) Conversion of Stock, Shares Issued Plan Name Plan Name [Axis] PEO PEO [Member] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Royalty Purchase Agreement Royalty Purchase Agreement [Member] Royalty Purchase Agreement Interest income Investment Income, Interest Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Authorized amount (up to) Sale Of Stock, Authorized, Amount Sale Of Stock, Authorized, Amount Contraceptive Landscape Review Agreement Contraceptive Landscape Review Agreement [Member] Contraceptive Landscape Review Agreement Accumulated deficit Retained Earnings [Member] Number of additional payment Royalty Agreement, Number Of Additional Payments Royalty Agreement, Number Of Additional Payments Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Proceeds from sale of royalty and milestone rights Proceeds From Sale Of Royalty And Milestone Rights Proceeds From Sale Of Royalty And Milestone Rights Sales based milestones amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Advanced written notice period Upfront License Fee, Advanced Written Notice, Period Upfront License Fee, Advanced Written Notice, Period Sale of Stock Sale of Stock [Domain] September 2023 Warrants September 2023 Warrants [Member] September 2023 Warrants Interest payable Increase (Decrease) in Interest Payable, Net Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Product and Service [Domain] Product and Service [Domain] Bayer Bayer Healthcare LLC [Member] Bayer Healthcare LLC Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Transaction costs Sale Of Royalty And Milestone Rights, Net Of Transaction Costs Sale Of Royalty And Milestone Rights, Net Of Transaction Costs Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Other current assets Increase (Decrease) in Other Current Assets Sale of stock, reimbursed and reimbursable issuance costs Sale Of Stock, Reimbursed And Reimbursable Issuance Costs Sale Of Stock, Reimbursed And Reimbursable Issuance Costs Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accrued expenses Accrued Liabilities, Current Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Agent Unit Warrants Agent Unit Warrants [Member] Agent Unit Warrants Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Liability related to the sale of future royalties Royalty Guarantees, Commitments, Gross Amount Royalty Guarantees, Commitments, Gross Amount Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Related Party Transactions [Abstract] Personnel-related (including stock-based compensation) Personnel-Related (Including Stock Based Compensation) [Member] Personnel-Related (Including Stock Based Compensation) Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Subsequent Event Subsequent Event [Member] Total lease cost Lease, Cost Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule of Lease Cost Lease, Cost [Table Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Non-dilutive grant funding, percentage excluded Non-Dilutive Grant Funding, Percentage Excluded Non-Dilutive Grant Funding, Percentage Excluded Lease Contractual Term [Axis] Lease Contractual Term [Axis] Non-cash interest expense and interest payable associated with the sale of future royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Equity Components [Axis] Equity Components [Axis] Former Stockholders of MBI Former Stockholders of MBI [Member] Former Stockholders of MBI Other advanced clinical stage programs Other Advanced Clinical Stage Programs [Member] Other Advanced Clinical Stage Programs Sildenafil Cream, 2.0% Sildenafil Cream, 2.0% [Member] Sildenafil Cream, 2.0% Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Number of reportable segments Number of Reportable Segments Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Underlying Awards Granted 2022 Stock Incentive Plan Underlying Awards Granted Two Thousand Twenty Two Stock Incentive Plan [Member] Underlying Awards Granted Two Thousand Twenty Two Stock Incentive Plan Warrant term Warrants and Rights Outstanding, Term Merger Agreement Merger Agreement [Member] Merger Agreement Supplemental disclosure of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Address, State or Province Entity Address, State or Province Principal payments on financing lease Financing cash flows from finance lease Finance Lease, Principal Payments DARE-HPV DARE-HPV [Member] DARE-HPV Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] 2026 (remaining) Operating And Finance Lease Liability Payments Remainder of Fiscal Year Operating And Finance Lease Liability Payments Remainder of Fiscal Year Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Related Party Related and Nonrelated Parties [Domain] Total current liabilities Liabilities, Current Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Individual: Individual [Axis] Other receivables Increase (Decrease) in Other Receivables Working capital Working Capital Increase (Deficit) Working Capital Increase (Deficit) Leased Properties Lessee, Finance Leases [Text Block] Future net sales Royalty Agreement, Future Net Sales, Percentage Royalty Agreement, Future Net Sales, Percentage Financing right-of-use assets obtained in exchange for new financing lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Other receivables Other Assets, Current Research and development Research and Development Expense [Member] Entity Entity [Domain] Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Royalty Purchase Agreements Royalty Purchase Agreements [Text Block] Royalty Purchase Agreements Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Project [Domain] Project [Domain] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Milestone payments, reimburse amount, PDUFA fees and other manufacturing expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Repayment of liability on sale of future royalties Repayment Of Liability On Sale Future Royalties Repayment Of Liability On Sale Future Royalties Entity Interactive Data Current Entity Interactive Data Current Operating lease cost Operating Lease, Cost Weighted Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Cash flows from operating activities Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract] Plan Name Plan Name [Domain] Total lease payments Operating And Finance Lease Liability Payments Due Operating And Finance Lease Liability Payments Due Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Supplemental investment (in shares) Class Of Warrant Or Right, Supplement Investment Share Amount Class Of Warrant Or Right, Supplement Investment Share Amount Equity [Abstract] Equity [Abstract] 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Segment Information Segment Reporting Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Convertible preferred stock, shares issued upon conversion Convertible Preferred Stock, Shares Issued upon Conversion Schedule of Supplemental Cash Flows Information Related to Leases Schedule Of Supplemental Cash Flows Information Related To Leases [Table Text Block] Schedule Of Supplemental Cash Flows Information Related To Leases XOMA XOMA (US) LLC [Member] XOMA (US) LLC Performance period Research And Development Arrangement, Performance Period Research And Development Arrangement, Performance Period Class of Warrant or Right [Table] Class of Warrant or Right [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Weighted average amortization period Weighted Average Amortization Period Weighted Average Amortization Period Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Selling, general and administrative Selling, General and Administrative Expense 2027 Operating And Finance Lease Liability Payments Due Year One Operating And Finance Lease Liability Payments Due Year One Depreciation and amortization Depreciation, Depletion and Amortization Other non-current assets Other Assets, Noncurrent Entity Central Index Key Entity Central Index Key PEO Name PEO Name Aggregate gross proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Direct program costs: Research And Development Direct Program Costs [Abstract] Research And Development Direct Program Costs Research and development: Research and Development Expense [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Digital Offering, LLC Digital Offering, LLC [Member] Digital Offering, LLC Present value of lease liabilities Finance Lease, Liability Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Maximum royalty payments Royalty Agreement, Maximum Royalty Payments Royalty Agreement, Maximum Royalty Payments Milestone payments Research And Development Milestone Payment Research and development milestone payment. Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Class of Stock [Domain] Class of Stock [Domain] Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Convertible notes issued, per share Share Price Deferred grant funding Deferred Grant Funding, Current Deferred Grant Funding, Current Subsequent Event Type Subsequent Event Type [Axis] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Indirect costs: Research And Development Expense, Indirect Costs Research And Development Expense, Indirect Costs Assets Assets [Abstract] Proceeds from royalties received Upfront payment from the sale of future royalties Proceeds from Royalties Received Underlying Security Market Price Change Underlying Security Market Price Change, Percent Class of Warrant or Right Class of Warrant or Right [Domain] Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Stockholders' equity Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] October 2016 Warrants October 2016 Warrants [Member] October 2016 Warrants Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Research and development Total research and development Research and Development Expense Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Lease liabilities long-term, operating Operating Lease, Liability, Noncurrent Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name Collaborative Arrangement Collaborative Arrangement [Member] Other non-current assets Increase (Decrease) in Other Noncurrent Assets Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Preclinical stage programs Preclinical Stage Programs [Member] Preclinical Stage Programs Purchase commitment, maximum amount committed Purchase Commitment, Maximum Amount Committed Purchase Commitment, Maximum Amount Committed Number of lowest sale prices Number Of Lowest Sale Prices Number Of Lowest Sale Prices Present value of lease liabilities Operating And Finance Lease Liability Operating And Finance Lease Liability Document Quarterly Report Document Quarterly Report Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Counterparty Name [Domain] Counterparty Name [Domain] Number of operating segments Number of Operating Segments Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Sildenafil Cream Sildenafil Cream, 3.6% [Member] Sildenafil Cream, 3.6% Quarterly payment period Royalty Agreement, Quarterly Payments, Period Royalty Agreement, Quarterly Payments, Period Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Related Party Related and Nonrelated Parties [Axis] Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount cash flow operations Cash Provided by (Used in) Operating Activity, Continuing Operation DARE-LARC1 DARE-LARC1 [Member] DARE-LARC1 Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Non-PEO NEO Non-PEO NEO [Member] Sale of Stock Sale of Stock [Axis] Series A Convertible Preferred Stock Series A Non Voting Convertible Preferred Stock [Member] Series A Non Voting Convertible Preferred Stock Name Trading Arrangement, Individual Name Incremental borrowing rate, amount over prime rate Operating Lease, Incremental Borrowing Rate, Prime Rate Operating Lease, Incremental Borrowing Rate, Prime Rate Equity Award Award Type [Domain] 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Internal rate of return Royalty Agreement, Internal Rate Of Return Royalty Agreement, Internal Rate Of Return Equity Awards Adjustments Equity Awards Adjustments [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Preferred stock, initial stated value per share Preferred Stock, Initial Stated Value Per Share Preferred Stock, Initial Stated Value Per Share Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Right-of-use assets - operating lease Increase (Decrease) In Operating Lease Right-of-Use Asset Increase (Decrease) In Operating Lease Right-of-Use Asset Preferred stock, convertible, threshold trading days Preferred Stock, Convertible, Threshold Trading Days Preferred Stock, Convertible, Threshold Trading Days Regulation A Offering Regulation A Offering [Member] Regulation A Offering Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] United in Endeavor, LLC United in Endeavor, LLC [Member] United in Endeavor, LLC Common stock issuable upon conversion of Series A Preferred Stock Preferred Stock [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Warrants outstanding (in usd per share) Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Revenue Revenue: Revenues [Abstract] 2026 (remaining) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Contra-R&D expenses Contra-R&D expenses Contra Research And Development Expense, Direct Program Costs Contra Research And Development Expense, Direct Program Costs Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Commitments and Contingencies Commitments Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Schedule of Finance Lease Liabilities Maturity Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Percentage of royalty rate Royalty Rate, Percentage Royalty Rate, Percentage Segments [Domain] Segments [Domain] Preferred stock, convertible, public offering proceeds, trigger Preferred Stock, Convertible, Public Offering Proceeds, Trigger Preferred Stock, Convertible, Public Offering Proceeds, Trigger Phase II Segment Phase II Segment [Member] Phase II Segment Income Statement Location Statement of Income Location, Balance [Axis] MBI MBI [Member] MBI Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Research and development services and royalty revenue Royalty [Member] Catalent and MilanaPharm Catalent and MilanaPharm [Member] Catalent and MilanaPharm Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Variable lease cost Variable Lease, Payment Number of consecutive trading days (in days) Number Of Consecutive Trading Days Number Of Consecutive Trading Days Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing, net of issuance costs Issuance Of Series A Convertible Preferred Stock And Warrants, Value Issuance Of Series A Convertible Preferred Stock And Warrants, Value Minimum Minimum [Member] Payments on note payable Repayments of Notes Payable Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Company Selected Measure Name Company Selected Measure Name Fair Value Measurement [Domain] Fair Value Measurement [Domain] Sale of stock, placement fee, percentage Sale of Stock, Placement Fee, Percentage Sale of Stock, Placement Fee, Percentage Preferred stock, $0.01 par value, 5,000,000 shares authorized; 4,999,620 and 0 designated Series A Convertible Preferred Stock at March 31, 2026 and December 31, 2025, respectively; 65,640 and 0 issued and outstanding at March 31, 2026 and December 31, 2025, respectively. Liquidation preference of $328,200 and $0 at March 31, 2026 and December 31, 2025, respectively Preferred Stock, Value, Issued Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Operating cash flows from operating leases Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Maximum percentage increase License And Services Agreement, Maximum Fee Increase, Percentage License And Services Agreement, Maximum Fee Increase, Percentage All Executive Categories All Executive Categories [Member] Common stock, $0.0001 par value; 240,000,000 shares authorized; 14,559,502 and 14,499,502 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Finance lease right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Other Receivables, Current Other Receivables, Current [Member] Other Receivables, Current Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Segment Information Segment Reporting, Policy [Policy Text Block] Commitments and contingencies (Note 9) Commitments and Contingencies Preferred stock, liquidation preference Preferred Stock, Liquidation Preference, Value Potential future payment Royalty Agreement, Maximum Potential Milestone Payments Royalty Agreement, Maximum Potential Milestone Payments Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Outstanding, Weighed Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Licensed Product or Process for Vaginal or Urological Use Licensed Product or Process for Vaginal or Urological Use [Member] Licensed Product or Process for Vaginal or Urological Use Business Combination Business Combination [Axis] Entity Small Business Entity Small Business Payments of stock issuance costs Payments of Stock Issuance Costs Preferred stock, convertible, conversion price Preferred Stock, Convertible, Conversion Price Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Document Transition Report Document Transition Report Square footage of office space Net Rentable Area Total lease payments Finance Lease, Liability, to be Paid Underlying Securities Award Underlying Securities Amount Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Project [Axis] Project [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Non-cash interest expense Non-Cash Interest Expense Non-Cash Interest Expense 2022 Stock Incentive Plan Two Thousand Twenty Two Stock Incentive Plan [Member] Two Thousand Twenty Two Stock Incentive Plan Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Potential future payment, percentage Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones Number of proceeding business period Number Of Proceeding Business Period Number Of Proceeding Business Period Royalty agreement, estimated amount of royalty obligation Royalty Agreement, Estimated Amount Of Royalty Obligation Royalty Agreement, Estimated Amount Of Royalty Obligation Operating lease liabilities Increase (Decrease) in Operating Lease Liability Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Agent Common Warrant Agent Common Warrant [Member] Agent Common Warrant Document Type Document Type Quantity of Warrants Outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Level 3 Fair Value, Inputs, Level 3 [Member] Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Additional paid-in capital Additional Paid in Capital Cash paid to stockholders' representative Payments to Stockholders' Representative in Business Combination Payments to Stockholders' Representative in Business Combination Product and Service [Axis] Product and Service [Axis] Outstanding advances Advances on Inventory Purchases Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue tier threshold, upper range limit Royalty Agreement, Revenue Tier Threshold, Incremental Amount Royalty Agreement, Revenue Tier Threshold, Incremental Amount All Individuals All Individuals [Member] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Total current assets Assets, Current Statistical Measurement Statistical Measurement [Axis] Liability related to the sale of future royalties, net Royalty Guarantees, Commitments, Amount Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the consolidated balance sheets: Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Royalty Interest Financing Sale Of Future Royalties [Text Block] Sale Of Future Royalties Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Current liabilities Liabilities, Current [Abstract] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Total operating expenses Operating Expenses Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Lincoln Park Capital Fund, LLC Lincoln Park Capital Fund, LLC [Member] Lincoln Park Capital Fund, LLC Total Operating And Finance Lease, Liability [Abstract] Operating And Finance Lease, Liability Level 1 Fair Value, Inputs, Level 1 [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Royalty Revenue Royalty Revenue [Member] Royalty Revenue Accrued expenses Increase (Decrease) in Accrued Liabilities Loss per common share - diluted (in usd per share) Earnings Per Share, Diluted Total research and development indirect costs Research And Development Expense, Indirect Costs, Net Research And Development Expense, Indirect Costs, Net Proceeds from research and development arrangement with federal government Proceeds From Research and Development Arrangement with Federal Government Proceeds From Research and Development Arrangement with Federal Government Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Issuance cost Offering Cost, Expense Title of 12(b) Security Title of 12(b) Security Contingent purchase price payments Royalty Agreement, Contingent Purchase Price Payments Royalty Agreement, Contingent Purchase Price Payments Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Hard cap rate Royalty Agreement, Hard Cap, Percentage Royalty Agreement, Hard Cap, Percentage Class of warrant or right, percentage common stock ownership after exercise Class of Warrant or Right, Percentage Common Stock Ownership After Exercise Class of Warrant or Right, Percentage Common Stock Ownership After Exercise Sale of stock, number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Accounts payable Increase (Decrease) in Other Accounts Payable Earnings Per Share [Abstract] Earnings Per Share [Abstract] Conversion of stock (in shares) Conversion of Stock, Shares Converted Issuable upon additional investment made number of securities called by warrants Class Of Warrant Or Right, Initial Royalty Warrant Issued Class Of Warrant Or Right, Initial Royalty Warrant Issued Contraceptive Product Grant Agreement Contraceptive Product Grant Agreement [Member] Contraceptive Product Grant Agreement Milestone payments rate Royalty Agreement, Milestone Payments, Percentage Royalty Agreement, Milestone Payments, Percentage Net proceeds from issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Prepaid expenses Increase (Decrease) in Prepaid Expense Exercised (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Clean Room Space Clean Room Space [Member] Clean Room Space Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Prepaid expenses Prepaid Expense Purchase And Registration Rights Agreement Purchase And Registration Rights Agreement [Member] Purchase And Registration Rights Agreement Direct program costs: Research And Development Expense, Direct Program Costs Research And Development Expense, Direct Program Costs Less: amount representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Registration statement period Sale Of Stock, Registration Statement Period Sale Of Stock, Registration Statement Period Award Timing Disclosures [Line Items] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Total lease payments Lessee, Operating Lease, Liability, to be Paid Renewal term of operating lease Lessee, Operating Lease, Renewal Term Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Stockholders' Equity Equity [Text Block] Ovaprene Ovaprene [Member] Ovaprene Preferred stock, percentage of stated value per share Preferred Stock, Percentage Of Stated Value Per Share Preferred Stock, Percentage Of Stated Value Per Share Net loss Net loss Net income (loss) Net Income (Loss) Attributable to Parent Subsequent Event [Table] Subsequent Event [Table] Forfeited or expired (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Expiration Date Trading Arrangement Expiration Date Upfront license fee paid Upfront License Fee, Amount Paid Upfront License Fee, Amount Paid Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Property and equipment, net Property, Plant and Equipment, Net Regulation A Offering Investor Warrants Regulation A Offering Investor Warrants [Member] Regulation A Offering Investor Warrants Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Adoption Date Trading Arrangement Adoption Date Reclassification of Prior Year Presentation Reclassification, Comparability Adjustment [Policy Text Block] Prepaid rent reclassified to finance lease right-of-use asset Prepaid Rent Reclassified To Finance Lease Right Of Use Asset Prepaid Rent Reclassified To Finance Lease Right Of Use Asset Shares issued (in usd per share) Shares Issued, Price Per Share Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Amount due upon execution License And Services Agreement, Amount Payable Upon Execution License And Services Agreement, Amount Payable Upon Execution Accounts receivable Increase (Decrease) in Accounts Receivable Series A Preferred Stock Series A Preferred Stock [Member] Entity Current Reporting Status Entity Current Reporting Status Net royalty payments rate Royalty Agreement, Net Royalty Payments, Percentage Royalty Agreement, Net Royalty Payments, Percentage Receivables [Abstract] Receivables [Abstract] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Cash flows from financing activities Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract] Loss from operations Loss from operations Operating Income (Loss) Supplemental investment payment Royalty Agreement, Supplement Investment Payment Royalty Agreement, Supplement Investment Payment Accumulated deficit Retained Earnings (Accumulated Deficit) Unamortized stock-based compensation expense Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Current portion of lease liability, finance Finance Lease, Liability, Current Hennepin License Agreement Hennepin License Agreement [Member] Hennepin License Agreement Class of Stock [Axis] Class of Stock [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Class of warrant or right, number of securities called by each warrant or right Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Grant Awards Grant Award [Text Block] Grant Award [Text Block] Subsequent Event Type Subsequent Event Type [Domain] Transaction price allocated to remaining performance obligations Transaction Price Allocated To Remaining Performance Obligations Transaction Price Allocated To Remaining Performance Obligations First commercial sale amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Schedule of Changes in the Liability Related to the Sale of Future Royalties Schedule Of Changes In The Liability Related To The Sale Of Future Royalties [Table Text Block] Schedule Of Changes In The Liability Related To The Sale Of Future Royalties Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Other (expense) income Other income, net Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Strategic Agreements Collaborative Arrangement Disclosure [Text Block] Weighted-average fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Repayment period on outstanding advances Outstanding Advances, Repayment Period Outstanding Advances, Repayment Period Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted average number of shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Sale of stock, price per share (in usd per share) Sale of Stock, Price Per Share Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Options to purchase number of outstanding shares of common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Phase 1 and Phase 1-ready clinical stage programs Phase 1 And Phase 1-Ready Clinical Stage Programs [Member] Phase 1 And Phase 1-Ready Clinical Stage Programs Leased Properties Lessee, Operating Leases [Text Block] Termination Date Trading Arrangement Termination Date Net cash (used in) provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Warrants Warrants [Member] Warrants Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Federal Subaward Federal Subaward [Member] Federal Subaward Current portion of liability related to the sale of future royalties Royalty Guarantees Commitments, Liability Related To Sale, Current Royalty Guarantees Commitments, Liability Related To Sale, Current Weighted-average discount rate, Operating leases Operating Lease, Weighted Average Discount Rate, Percent Schedule of Stock Option Activity for Amended 2014 Plan and Related Information Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic XACIATO XACIATO [Member] XACIATO Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Synthetic Synthetic [Member] Synthetic Warrants and rights outstanding (in shares) Relative fair value of Initial Royalty Warrant Warrants and Rights Outstanding Initial payment Grants Receivable Restricted cash included in other non-current assets Restricted Cash and Cash Equivalent, Noncurrent Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Related Party Transaction [Domain] Related Party Transaction [Domain] Subsequent Events [Abstract] Subsequent Events [Abstract] Segment Reporting [Abstract] Preferred stock, non-compounded rate of return, percentage Preferred Stock, Non-Compounded Rate Of Return, Percentage Preferred Stock, Non-Compounded Rate Of Return, Percentage Cost of revenues Cost of Revenue Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Schedule of Weighted Average Remaining Lease Terms and Discount Rates Weighted Average Remaining Lease Terms And Discount Rates [Table Text Block] Weighted Average Remaining Lease Terms And Discount Rates Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (in shares) Common Stock, Shares, Issued Current asset payment included in accounts payable Current Asset Payment Included In Accounts Payable Current Asset Payment Included In Accounts Payable Weighted-average remaining lease term, Operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Indirect cost allowance percentage Grant Awards, Indirect Cost Allowance, Percentage Grant Awards, Indirect Cost Allowance, Percentage Use of Estimates Use of Estimates, Policy [Policy Text Block] Interest on finance lease liability Operating cash flows from finance lease Finance Lease, Interest Payment on Liability Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Subsequent Events Subsequent Events [Text Block] Deposits Increase (Decrease) in Deposit Assets Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Canceled/forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of Shares Underlying Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Reportable Segment Reportable Segment [Member] Reportable Segment Total liabilities Liabilities Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing, net of issuance costs (in shares) Issuance Of Series A Convertible Preferred Stock And Warrants, Shares Issuance Of Series A Convertible Preferred Stock And Warrants, Shares ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Investor Warrants Investor Warrants [Member] Investor Warrants Douglas License Agreement Douglas License Agreement [Member] Douglas License Agreement Operating expenses Segment operating expenses: Operating Expenses [Abstract] Other current assets Prepaid Expense, Current Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Effective annual interest rate Royalty Agreement, Effective Annual Interest Rate, Percentage Royalty Agreement, Effective Annual Interest Rate, Percentage Indirect costs: Research And Development Indirect Costs [Abstract] Research And Development Indirect Costs Stock options Stock Options [Member] Stock Options Sale of stock, percentage of warrants issuable Sale Of Stock, Percentage Of Warrants Issuable Sale Of Stock, Percentage Of Warrants Issuable Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Counterparty Name [Axis] Counterparty Name [Axis] Subsequent Event [Line Items] Subsequent Event [Line Items] Shares available not to issue or sell more than (in shares) Sale of Stock, Shares Available Not To Issue Or Sell Sale of Stock, Shares Available not to Issue or Sell Common stock Common stock warrants Common Stock [Member] Organon Organon [Member] Organon Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Finance Lease Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Payment of additional consideration Payment of Additional Consideration in Business Combination Payment of Additional Consideration in Business Combination Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain]